Compare ARDX & SMWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARDX | SMWB |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 862.3M | 778.8M |
| IPO Year | 2014 | 2021 |
| Metric | ARDX | SMWB |
|---|---|---|
| Price | $3.24 | $8.92 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 8 |
| Target Price | ★ $12.90 | $10.83 |
| AVG Volume (30 Days) | ★ 4.1M | 485.5K |
| Earning Date | 10-29-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,607,000.00 | N/A |
| Revenue This Year | $19.98 | $11.98 |
| Revenue Next Year | $27.70 | $11.01 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.18 | $2.22 |
| 52 Week High | $8.40 | $9.50 |
| Indicator | ARDX | SMWB |
|---|---|---|
| Relative Strength Index (RSI) | 29.24 | 61.43 |
| Support Level | N/A | $7.83 |
| Resistance Level | $3.63 | $9.03 |
| Average True Range (ATR) | 0.11 | 0.43 |
| MACD | 0.01 | 0.10 |
| Stochastic Oscillator | 12.50 | 81.19 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Similarweb Ltd provides digital data and analytics that power critical business decisions. The group recognizes revenue from subscriptions to the platform and other subscription products on a straight-line basis over the term of the contract subscription period beginning on the date access to the platform is granted, provided all other revenue recognition criteria have been met. It has geographic presence in Israel, the United States, the United Kingdom, Asia Pacific, Europe, and Other. The group generates the majority of its revenue from the United States.